
Dengue Vaccine Market By Vaccine Type(Live Attenuated Vaccines, Chimeric Live Attenuated Vaccines, Other Vaccine Type), By End-User (Hospitals, Government Institutes, Other), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2023-2032
38257
June 2023
179
Report Overview
The Global Dengue Vaccine Market size is expected to be worth around USD 1,367.7 Mn by 2032 from USD 457 Mn in 2022, growing at a CAGR of 11.9% during the forecast period from 2023 to 2032.
A wide range of immunization options against the dangerous dengue fever is what the market for dengue vaccines, encompassing the global market landscape, seeks to provide. These vaccines are ingeniously designed to induce an immune response in the human body, thereby enhancing the body's defense against the pernicious virus. With safety, efficacy, and global accessibility as its top priorities, the market strives to meet the urgent requirements of individuals worldwide.
With the advent of a previously unheard-of vaccine known as Dengvaxia, which was effectively approved by the esteemed FDA in 2019, the global dengue vaccine market experienced a significant breakthrough. This revolutionary vaccine has reduced the incidence of dengue fever by an astounding 60 percent among the immunized population.
In recent years, the dengue vaccine market has witnessed an increase in investments, as pharmaceutical giants such as Sanofi and Takeda have aggressively pursued vaccine research and development. Moreover, these industry titans have worked diligently to incorporate their vaccines into existing public health initiatives designed to combat dengue fever in countries where it is endemic.
In the coming years, eminent industry analysts anticipate a meteoric growth trajectory for the global dengue vaccine market. This favorable ascent will be propelled by the advent of novel vaccines and the increased acceptability and adoption of existing vaccines. The lion's share of this growth is anticipated to emanate from emerging markets, which will be predominantly concentrated in Asia and Latin America.
As the primary driver of the dengue vaccine market, the pharmaceutical industry, bolstered by Sanofi and Takeda, invests lavishly in the development of innovative vaccines that will ultimately save lives and combat the dengue threat.
Naturally, as with any innovative medical development, ethical dilemmas arise regarding the development and implementation of dengue vaccines. Accessibility, affordability, and security are at the vanguard of these ethical complexities. In this dynamic environment, it is of the utmost importance that all stakeholders collaborate harmoniously and address these issues with discretion to ensure responsible progress.
To continue its ascent and achieve long-term success, the global dengue vaccine market must prioritize openness, clarity, and responsibility. This requires an unambiguous commitment from all stakeholders to provide clear and concise information regarding the development, regulation, and distribution of vaccines.
The global dengue vaccine market offers a wide range of commercial opportunities, encompassing the development of novel vaccines, the seamless integration of existing vaccines into public health programs, and the establishment of innovative distribution channels and marketing strategies. This expanding market presents abundant opportunities for pharmaceutical giants, healthcare providers, and a variety of other stakeholders.
Driving factors
Rising Global Demand
The global dengue vaccine market is expanding, and the increasing prevalence of dengue fever around the world is the primary driver of this growth. Dengue fever is an ailment transmitted by mosquitoes that affects millions of people annually, primarily in tropical and subtropical regions. This disease's high prevalence has prompted increased awareness and prevention efforts, as well as advances in vaccine development.
Changing Legislation
Governments in endemic regions have instituted immunization programs to reduce the number of cases in response to the severity of this disease. These initiatives have contributed to the growth of the market for dengue vaccines, making it one of the most promising sectors of the global pharmaceutical industry.
Strategic Disruptors
Nevertheless, the regulatory landscape is constantly evolving, and any changes to regulations could have a substantial impact on the market. Companies will need to monitor prospective changes and adapt their strategies accordingly.
Emerging Trends
Despite the promising growth of the market for dengue vaccines, there are a number of potential factors that could have an impact on the competitive landscape. The emergence of new vaccine technologies or alternative treatment methods, for instance, could threaten the market dominance of established actors.
Growing Awareness
Finally, it is essential to consider any emerging trends or changes in consumer behavior that may have an impact on the market for dengue vaccine. As more people become aware of the dangers associated with dengue fever, there may be a shift toward preventative measures such as vaccination, which could fuel the market's growth.
Restraining Factors
Concerns Regarding the Global Dengue Vaccine Market's Security
Vaccines are a tool used in the medical field to stop the occurrence and transmission of disease. Vaccines against a variety of diseases, including dengue fever, have been developed. Dengue fever is a disease transmitted by mosquitoes that is prevalent in many tropical and subtropical areas. An estimated 400 million cases of dengue fever are reported each year, with a significant number leading to hospitalization or death.
Difficulties with Dengue Immunization
Concerns regarding the safety and efficacy of vaccines are one of the most significant restraints on the global dengue vaccine market. To ensure that they are willing to be immunized, it is essential for individuals to have faith in vaccines. However, there have been instances of vaccines causing adverse effects, leading to concerns regarding their safety. Given the potential severity of dengue fever, any adverse effects of the vaccine would harm the market. Vaccine providers must therefore ensure that they conduct exhaustive testing and monitoring of the vaccine.
Accessibility Restraints Dengue Vaccine Market
The complexity of immunization strategies required to immunize against dengue fever is an additional limiting factor. In contrast to other diseases for which a single vaccination is sufficient, dengue fever requires multiple doses to be effective. Additionally, the vaccine should not be administered to individuals who have never been afflicted with one of the strains of the dengue virus. As a result, the vaccine must target previously infected individuals, which may necessitate screening and testing.
Dengue Vaccine vs. Vector Control Measures
In addition to the complexity of immunization strategies, restricted access is another factor restraining the global dengue vaccine market. Dengue fever is prevalent in many tropical and subtropical regions where the population may have limited access to vaccines. In such areas, the healthcare infrastructure may be underdeveloped, making the provision of vaccines difficult. In addition, vaccine providers may encounter economic obstacles when supplying vaccines to highly prevalent disease regions. This lack of access to vaccines can substantially hinder market expansion.
Costs and Advantages of Dengue Vaccines
Effective vector control measures, such as the use of mosquito nets, insecticides, and educational campaigns, have reduced the prevalence of dengue fever. As the market for dengue vaccines expands, however, it may encounter competition from these control measures. Because vector control measures are cost-effective and simple to implement, individuals may choose them over the vaccine. Consequently, vaccine providers must ensure that the vaccine is priced competitively and offers additional advantages in comparison to control measures.
Vaccine Type Analysis
Dengue fever, a mosquito-borne viral disease that has affected millions of people worldwide, primarily in underdeveloped nations, is currently spreading throughout the world. Given this, a vaccine to prevent or control this disease's spread is a high goal. The Live Attenuated Vaccines Segment has led the global dengue vaccine market's growth.
The Live Attenuated Vaccines Segment—which includes Dengvaxia—leads the global dengue vaccine market. The live virus induces an immune response and disease immunity in this vaccine. The vaccine protects against all four dengue virus variants.
Economic growth in emerging markets is one driver driving Live Attenuated Vaccines Segment adoption. As these countries expand, healthcare, including vaccines, the need has increased. In addition, these economies are investing in healthcare infrastructure and extending access to services, making it possible for more people to get vaccinated.
The consumer trend and behavior toward this form of vaccine is another reason driving the adoption of the Live Attenuated Vaccines Segment. Vaccines protect individuals and the community, and awareness has grown in recent years. People are more ready to get vaccinated and invest in their health, making the Live Attenuated Vaccines Segment popular.
This growth can be attributed to rising vaccine demand, economic growth in emerging economies, vaccine importance, and vaccine research and development advancements.
End-User Analysis
In addition to vaccine type, the end-user segment of the global dengue vaccine market is crucial. Hospitals lead the market.
The Hospitals Segment, which includes private and public hospitals, dominates the global dengue vaccine market. This can be attributed to the fact that hospitals provide healthcare services, including vaccines, over the world.
Like the Live Attenuated Vaccines Segment, rising economies are driving Hospital Segment adoption. More people are seeking high-quality healthcare services, including immunizations, as their incomes rise. Hospital services have increased, making them more accessible.
Hospitals are becoming more popular for healthcare services including immunizations. Greater awareness of the importance of preventative care and a desire for better-quality healthcare services are driving the trend toward seeking out healthcare services from hospitals.
This growth can be attributed to economic growth in emerging economies, the trend toward seeking healthcare services in hospitals, and advancements in hospital infrastructure and technology.
Key Market Segments
By Product
- CYD-TDV (Dengvaxia)
By Vaccine Type
- Live Attenuated Vaccines
- Chimeric Live Attenuated Vaccines
- Other Vaccine Type
By End-User
- Hospitals
- Government Institutes
- Specialty Clinics
- Other End-Users
Growth Opportunity
Targeting High-Risk Areas Expanding Distribution and Access
This growth opportunity entails improving dengue vaccine market availability and accessibility in dengue-prone regions like Southeast Asia, Latin America, and the Caribbean. Partnerships with local health officials, community engagement, and vaccination facilities in disease-prone areas could accomplish this.
Researching Multivalent Dengue Vaccines
Multivalent dengue vaccinations that protect against all four serotypes offer a huge growth opportunity. Currently, authorized vaccinations defend against individual serotypes or a combination of them. A vaccine that targets all serotypes would be more effective and marketable.
Vaccination Campaigns
Dengue fever awareness and vaccination can boost vaccine demand. This growth opportunity entails large-scale vaccination campaigns, collaborating with healthcare organizations, and using digital channels to educate the public about the vaccine's benefits and availability.
Travel medicine
Travelers to areas where the disease is endemic should be wary of dengue fever. Expanding the dengue vaccine market in travel medicine gives an opportunity for growth. The vaccine can be more widely used by travelers if travel clinics, tour operators, and travel insurance companies work together to promote vaccination as a preventative step.
Vaccine Durability Research:
Dengue vaccine market research and booster doses give a growth opportunity for vaccine makers. Understanding the vaccine's long-term efficacy and the best booster dosage timing could help sustain market growth by assuring product demand and addressing possible protection gaps.
Latest Trends
Dengue Vaccines Drive Market Growth
Millions of people in tropical and subtropical regions are annually infected by the mosquito-borne Dengue Fever virus. Dengue is untreatable, thus vaccination is crucial. The need for dengue virus vaccines has increased globally, which has led to the development of innovative vaccines and vaccine delivery methods.
Tetravalent Dengue Vaccines Protect 100%
The development of tetravalent dengue vaccinations in recent years has advanced dengue fever prevention. In areas with numerous dengue serotypes, these vaccinations protect against all four. Dengvaxia, created by Sanofi Pasteur, is a leading tetravalent dengue vaccine licensed in over 20 countries. Safety and efficacy concerns have led to regulatory limits in various nations.
Innovative Dengue Vaccination Delivery Changes
The development of tetravalent dengue vaccines and the utilization of innovative vaccine delivery methods have received substantial attention. Patches and micro-needles are attractive vaccine delivery methods due to their ease of use, lack of needles, and potential for greater compliance. Vaxxas and NanoPass Technologies are among the companies actively working on the development of such vaccinations.
New Dengue Vaccines for Everyone
The global dengue vaccine market is also shaped by the development of vaccine candidates for different age groups. Dengue vaccinations are licensed for adults and children 9-16 years old. However, newborns and young children, who are most at risk of dengue fever sequelae, are the focus of vaccine development. Companies like Takeda and Butantan Institute are working on vaccine development for these age ranges.
Integration Improves Dengue Vaccines.
Finally, dengue vaccination integration with other immunization programs is expected to be a major market development in the next years. With the development of combination vaccines, you can now prevent numerous diseases with one vaccination. Dengue vaccine integration with other vaccinations can increase immunization program efficiency and coverage, especially in areas with limited healthcare access.
Regional Analysis
The dengue vaccine market in the Asia-Pacific region is dominated by a number of factors that contribute to its significant presence and growth. Numerous countries in the Asia-Pacific region report a substantial number of dengue fever cases each year, resulting in a significant burden of the disease. This frequency increases the need for effective preventative measures, such as vaccines.
India, China, and Indonesia are among the most populous countries in the globe and are located in this region. As a result of the large population, there is a substantial market opportunity for dengue vaccines, as a greater number of individuals may require immunization.
Governments throughout the Asia-Pacific region have instituted vaccination programs in response to the urgency of combating dengue fever. National immunization campaigns and proactive disease control efforts have fostered the growth of the dengue vaccine market.
Numerous Asian countries have actively participated in the development and testing of dengue vaccines. Institutions and pharmaceutical companies in countries such as India, China, and Thailand have made significant strides in vaccine research, which has contributed to the availability of locally produced vaccines.
Rapid economic growth in a number of Asia-Pacific countries has led to an increase in healthcare spending and accessibility. This has resulted in a greater demand for preventative healthcare measures, such as vaccinations, thereby creating a market conducive to dengue vaccines. Actively supporting dengue control initiatives in the region are the World Health Organization (WHO) and the Asian Development Bank (ADB). Collaboration between countries has facilitated the distribution and accessibility of vaccines, thereby accelerating market growth.
Key Regions and Countries
North America
- US
- Canada
- Mexico
Western Europe
- Germany
- France
- The UK
- Spain
- Italy
- Portugal
- Ireland
- Austria
- Switzerland
- Benelux
- Nordic
- Rest of Western Europe
Eastern Europe
- Russia
- Poland
- The Czech Republic
- Greece
- Rest of Eastern Europe
APAC
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- Indonesia
- Malaysia
- Philippines
- Singapore
- Thailand
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Colombia
- Chile
- Argentina
- Costa Rica
- Rest of Latin America
Middle East & Africa
- Algeria
- Egypt
- Israel
- Kuwait
- Nigeria
- Saudi Arabia
- South Africa
- Turkey
- United Arab Emirates
- Rest of MEA
Key Players Analysis
Sanofi Pasteur has been the market leader in dengue vaccine development. It is believed that its product Dengvaxia, the first dengue vaccine licensed by the U.S. Food and Drug Administration, has the potential to protect against all four serotypes of the dengue virus.
Takeda has also become a significant player in the global dengue vaccine market with its Dengue TAK-003 product. It has been demonstrated to prevent dengue fever caused by serotypes 1, 2, 3, and 4.
Merck Sharp & Dohme (MSD), which has introduced its own dengue vaccine, DengueLink Tetravalent, in several Latin American nations, and Bharat Biotech, which has developed India's first-ever dengue vaccine, Dengvaxia, are also significant players.
Overall, the global dengue vaccine market is extremely competitive, with numerous players vying for a larger market share. However, given the global prevalence of dengue fever, this industry has enormous development and expansion potential.
Top Key Players in Dengue Vaccine Market
- Sanofi Pasteur
- Takeda Pharmaceutical Company
- Biological E Limited
- Panacea Biotec
- Serum Institute of India Pvt. Ltd
- GeneOne Life Science
- Medigen Vaccine Biologics
- Panacea Biotec
- Butantan Institute
- Sun Pharmaceutical Industries Ltd
- Other Key Players
Recent Development
- In 2023, Advances in vaccine delivery systems To improve the efficacy and convenience of dengue vaccines, researchers have recently focused on devising innovative vaccine delivery systems.
- In 2022, mRNA-based dengue vaccine advancements in 2022 scientists made progress on mRNA-based dengue vaccines.
- In 2021, encouraging results for vaccine candidates TV003/TV005 National Institutes of Health (NIH) researchers reported promising results from Phase 2 clinical trials of TV003 and TV005 dengue vaccine candidates 2021.
- In 2020, Phase 3 clinical trials were concluded, showing efficacy against all four serotypes of dengue virus. These encouraging results inspired optimism for a novel vaccine option.
- In 2020, Takeda Pharmaceutical Company, in collaboration with the Takeda Vaccines Division, continued the development of its dengue vaccine candidate, TAK-003.
- In 2019, Dengvaxia's approval 2019 and ongoing research the World Health Organization (WHO) approved the Dengvaxia Dengue Vaccine for the first time.
Report Scope:
Report Features Description Market Value (2022) USD 457 Mn Forecast Revenue (2032) USD 1,367.7 Mn CAGR (2023-2032) 11.9% Base Year for Estimation 2022 Historic Period 2016-2022 Forecast Period 2023-2032 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Product (CYD-TDV (Dengvaxia)), By Vaccine Type(Live Attenuated Vaccines, Chimeric Live Attenuated Vaccines, Other Vaccine Types), By End-User (Hospitals, Government Institutes, Specialty Clinics, Other End-Users) Regional Analysis North America – The US, Canada, & Mexico; Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA Competitive Landscape Sanofi Pasteur, Takeda Pharmaceutical Company, Biological E Limited, Panacea Biotec, Serum Institute of India Pvt. Ltd, GeneOne Life Science, Medigen Vaccine Biologics, Panacea Biotec, Butantan Institute, Sun Pharmaceutical Industries Ltd, Other Key Players Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) - Sanofi Pasteur
- Takeda Pharmaceutical Company
- Biological E Limited
- Panacea Biotec
- Serum Institute of India Pvt. Ltd
- GeneOne Life Science
- Medigen Vaccine Biologics
- Panacea Biotec
- Butantan Institute
- Sun Pharmaceutical Industries Ltd
- Other Key Players
- 1. Executive Summary
- 1.1. Definition
- 1.2. Taxonomy
- 1.3. Research Scope
- 1.4. Key Analysis
- 1.5. Key Findings by Major Segments
- 1.6. Top strategies by Major Players
- 2. Global Dengue Vaccine Market Overview
- 2.1. Dengue Vaccine Market Dynamics
- 2.1.1. Drivers
- 2.1.2. Opportunities
- 2.1.3. Restraints
- 2.1.4. Challenges
- 2.2. Macro-economic Factors
- 2.3. Regulatory Framework
- 2.4. Market Investment Feasibility Index
- 2.5. PEST Analysis
- 2.6. PORTER’S Five Force Analysis
- 2.7. Drivers & Restraints Impact Analysis
- 2.8. Industry Chain Analysis
- 2.9. Cost Structure Analysis
- 2.10. Marketing Strategy
- 2.11. Russia-Ukraine War Impact Analysis
- 2.12. Opportunity Map Analysis
- 2.13. Market Competition Scenario Analysis
- 2.14. Product Life Cycle Analysis
- 2.15. Opportunity Orbits
- 2.16. Manufacturer Intensity Map
- 2.17. Major Companies sales by Value & Volume
- 2.1. Dengue Vaccine Market Dynamics
- 3. Global Dengue Vaccine Market Analysis, Opportunity and Forecast, 2016-2032
- 3.1. Global Dengue Vaccine Market Analysis, 2016-2021
- 3.2. Global Dengue Vaccine Market Opportunity and Forecast, 2023-2032
- 3.3. Global Dengue Vaccine Market Analysis, Opportunity and Forecast, By By Product, 2016-2032
- 3.3.1. Global Dengue Vaccine Market Analysis by By Product: Introduction
- 3.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Product, 2016-2032
- 3.3.3. CYD-TDV (Dengvaxia)
- 3.4. Global Dengue Vaccine Market Analysis, Opportunity and Forecast, By By Vaccine Type, 2016-2032
- 3.4.1. Global Dengue Vaccine Market Analysis by By Vaccine Type: Introduction
- 3.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Vaccine Type, 2016-2032
- 3.4.3. Live Attenuated Vaccines
- 3.4.4. Chimeric Live Attenuated Vaccines
- 3.5. Global Dengue Vaccine Market Analysis, Opportunity and Forecast, By By End-User, 2016-2032
- 3.5.1. Global Dengue Vaccine Market Analysis by By End-User: Introduction
- 3.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By End-User, 2016-2032
- 3.5.3. Hospitals
- 3.5.4. Government Institutes
- 3.5.5. Specialty Clinics
- 4. North America Dengue Vaccine Market Analysis, Opportunity and Forecast, 2016-2032
- 4.1. North America Dengue Vaccine Market Analysis, 2016-2021
- 4.2. North America Dengue Vaccine Market Opportunity and Forecast, 2023-2032
- 4.3. North America Dengue Vaccine Market Analysis, Opportunity and Forecast, By By Product, 2016-2032
- 4.3.1. North America Dengue Vaccine Market Analysis by By Product: Introduction
- 4.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Product, 2016-2032
- 4.3.3. CYD-TDV (Dengvaxia)
- 4.4. North America Dengue Vaccine Market Analysis, Opportunity and Forecast, By By Vaccine Type, 2016-2032
- 4.4.1. North America Dengue Vaccine Market Analysis by By Vaccine Type: Introduction
- 4.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Vaccine Type, 2016-2032
- 4.4.3. Live Attenuated Vaccines
- 4.4.4. Chimeric Live Attenuated Vaccines
- 4.5. North America Dengue Vaccine Market Analysis, Opportunity and Forecast, By By End-User, 2016-2032
- 4.5.1. North America Dengue Vaccine Market Analysis by By End-User: Introduction
- 4.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By End-User, 2016-2032
- 4.5.3. Hospitals
- 4.5.4. Government Institutes
- 4.5.5. Specialty Clinics
- 4.6. North America Dengue Vaccine Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 4.6.1. North America Dengue Vaccine Market Analysis by Country : Introduction
- 4.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 4.6.2.1. The US
- 4.6.2.2. Canada
- 4.6.2.3. Mexico
- 5. Western Europe Dengue Vaccine Market Analysis, Opportunity and Forecast, 2016-2032
- 5.1. Western Europe Dengue Vaccine Market Analysis, 2016-2021
- 5.2. Western Europe Dengue Vaccine Market Opportunity and Forecast, 2023-2032
- 5.3. Western Europe Dengue Vaccine Market Analysis, Opportunity and Forecast, By By Product, 2016-2032
- 5.3.1. Western Europe Dengue Vaccine Market Analysis by By Product: Introduction
- 5.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Product, 2016-2032
- 5.3.3. CYD-TDV (Dengvaxia)
- 5.4. Western Europe Dengue Vaccine Market Analysis, Opportunity and Forecast, By By Vaccine Type, 2016-2032
- 5.4.1. Western Europe Dengue Vaccine Market Analysis by By Vaccine Type: Introduction
- 5.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Vaccine Type, 2016-2032
- 5.4.3. Live Attenuated Vaccines
- 5.4.4. Chimeric Live Attenuated Vaccines
- 5.5. Western Europe Dengue Vaccine Market Analysis, Opportunity and Forecast, By By End-User, 2016-2032
- 5.5.1. Western Europe Dengue Vaccine Market Analysis by By End-User: Introduction
- 5.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By End-User, 2016-2032
- 5.5.3. Hospitals
- 5.5.4. Government Institutes
- 5.5.5. Specialty Clinics
- 5.6. Western Europe Dengue Vaccine Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 5.6.1. Western Europe Dengue Vaccine Market Analysis by Country : Introduction
- 5.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 5.6.2.1. Germany
- 5.6.2.2. France
- 5.6.2.3. The UK
- 5.6.2.4. Spain
- 5.6.2.5. Italy
- 5.6.2.6. Portugal
- 5.6.2.7. Ireland
- 5.6.2.8. Austria
- 5.6.2.9. Switzerland
- 5.6.2.10. Benelux
- 5.6.2.11. Nordic
- 5.6.2.12. Rest of Western Europe
- 6. Eastern Europe Dengue Vaccine Market Analysis, Opportunity and Forecast, 2016-2032
- 6.1. Eastern Europe Dengue Vaccine Market Analysis, 2016-2021
- 6.2. Eastern Europe Dengue Vaccine Market Opportunity and Forecast, 2023-2032
- 6.3. Eastern Europe Dengue Vaccine Market Analysis, Opportunity and Forecast, By By Product, 2016-2032
- 6.3.1. Eastern Europe Dengue Vaccine Market Analysis by By Product: Introduction
- 6.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Product, 2016-2032
- 6.3.3. CYD-TDV (Dengvaxia)
- 6.4. Eastern Europe Dengue Vaccine Market Analysis, Opportunity and Forecast, By By Vaccine Type, 2016-2032
- 6.4.1. Eastern Europe Dengue Vaccine Market Analysis by By Vaccine Type: Introduction
- 6.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Vaccine Type, 2016-2032
- 6.4.3. Live Attenuated Vaccines
- 6.4.4. Chimeric Live Attenuated Vaccines
- 6.5. Eastern Europe Dengue Vaccine Market Analysis, Opportunity and Forecast, By By End-User, 2016-2032
- 6.5.1. Eastern Europe Dengue Vaccine Market Analysis by By End-User: Introduction
- 6.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By End-User, 2016-2032
- 6.5.3. Hospitals
- 6.5.4. Government Institutes
- 6.5.5. Specialty Clinics
- 6.6. Eastern Europe Dengue Vaccine Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 6.6.1. Eastern Europe Dengue Vaccine Market Analysis by Country : Introduction
- 6.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 6.6.2.1. Russia
- 6.6.2.2. Poland
- 6.6.2.3. The Czech Republic
- 6.6.2.4. Greece
- 6.6.2.5. Rest of Eastern Europe
- 7. APAC Dengue Vaccine Market Analysis, Opportunity and Forecast, 2016-2032
- 7.1. APAC Dengue Vaccine Market Analysis, 2016-2021
- 7.2. APAC Dengue Vaccine Market Opportunity and Forecast, 2023-2032
- 7.3. APAC Dengue Vaccine Market Analysis, Opportunity and Forecast, By By Product, 2016-2032
- 7.3.1. APAC Dengue Vaccine Market Analysis by By Product: Introduction
- 7.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Product, 2016-2032
- 7.3.3. CYD-TDV (Dengvaxia)
- 7.4. APAC Dengue Vaccine Market Analysis, Opportunity and Forecast, By By Vaccine Type, 2016-2032
- 7.4.1. APAC Dengue Vaccine Market Analysis by By Vaccine Type: Introduction
- 7.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Vaccine Type, 2016-2032
- 7.4.3. Live Attenuated Vaccines
- 7.4.4. Chimeric Live Attenuated Vaccines
- 7.5. APAC Dengue Vaccine Market Analysis, Opportunity and Forecast, By By End-User, 2016-2032
- 7.5.1. APAC Dengue Vaccine Market Analysis by By End-User: Introduction
- 7.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By End-User, 2016-2032
- 7.5.3. Hospitals
- 7.5.4. Government Institutes
- 7.5.5. Specialty Clinics
- 7.6. APAC Dengue Vaccine Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 7.6.1. APAC Dengue Vaccine Market Analysis by Country : Introduction
- 7.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 7.6.2.1. China
- 7.6.2.2. Japan
- 7.6.2.3. South Korea
- 7.6.2.4. India
- 7.6.2.5. Australia & New Zeland
- 7.6.2.6. Indonesia
- 7.6.2.7. Malaysia
- 7.6.2.8. Philippines
- 7.6.2.9. Singapore
- 7.6.2.10. Thailand
- 7.6.2.11. Vietnam
- 7.6.2.12. Rest of APAC
- 8. Latin America Dengue Vaccine Market Analysis, Opportunity and Forecast, 2016-2032
- 8.1. Latin America Dengue Vaccine Market Analysis, 2016-2021
- 8.2. Latin America Dengue Vaccine Market Opportunity and Forecast, 2023-2032
- 8.3. Latin America Dengue Vaccine Market Analysis, Opportunity and Forecast, By By Product, 2016-2032
- 8.3.1. Latin America Dengue Vaccine Market Analysis by By Product: Introduction
- 8.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Product, 2016-2032
- 8.3.3. CYD-TDV (Dengvaxia)
- 8.4. Latin America Dengue Vaccine Market Analysis, Opportunity and Forecast, By By Vaccine Type, 2016-2032
- 8.4.1. Latin America Dengue Vaccine Market Analysis by By Vaccine Type: Introduction
- 8.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Vaccine Type, 2016-2032
- 8.4.3. Live Attenuated Vaccines
- 8.4.4. Chimeric Live Attenuated Vaccines
- 8.5. Latin America Dengue Vaccine Market Analysis, Opportunity and Forecast, By By End-User, 2016-2032
- 8.5.1. Latin America Dengue Vaccine Market Analysis by By End-User: Introduction
- 8.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By End-User, 2016-2032
- 8.5.3. Hospitals
- 8.5.4. Government Institutes
- 8.5.5. Specialty Clinics
- 8.6. Latin America Dengue Vaccine Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 8.6.1. Latin America Dengue Vaccine Market Analysis by Country : Introduction
- 8.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 8.6.2.1. Brazil
- 8.6.2.2. Colombia
- 8.6.2.3. Chile
- 8.6.2.4. Argentina
- 8.6.2.5. Costa Rica
- 8.6.2.6. Rest of Latin America
- 9. Middle East & Africa Dengue Vaccine Market Analysis, Opportunity and Forecast, 2016-2032
- 9.1. Middle East & Africa Dengue Vaccine Market Analysis, 2016-2021
- 9.2. Middle East & Africa Dengue Vaccine Market Opportunity and Forecast, 2023-2032
- 9.3. Middle East & Africa Dengue Vaccine Market Analysis, Opportunity and Forecast, By By Product, 2016-2032
- 9.3.1. Middle East & Africa Dengue Vaccine Market Analysis by By Product: Introduction
- 9.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Product, 2016-2032
- 9.3.3. CYD-TDV (Dengvaxia)
- 9.4. Middle East & Africa Dengue Vaccine Market Analysis, Opportunity and Forecast, By By Vaccine Type, 2016-2032
- 9.4.1. Middle East & Africa Dengue Vaccine Market Analysis by By Vaccine Type: Introduction
- 9.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By Vaccine Type, 2016-2032
- 9.4.3. Live Attenuated Vaccines
- 9.4.4. Chimeric Live Attenuated Vaccines
- 9.5. Middle East & Africa Dengue Vaccine Market Analysis, Opportunity and Forecast, By By End-User, 2016-2032
- 9.5.1. Middle East & Africa Dengue Vaccine Market Analysis by By End-User: Introduction
- 9.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By By End-User, 2016-2032
- 9.5.3. Hospitals
- 9.5.4. Government Institutes
- 9.5.5. Specialty Clinics
- 9.6. Middle East & Africa Dengue Vaccine Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 9.6.1. Middle East & Africa Dengue Vaccine Market Analysis by Country : Introduction
- 9.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 9.6.2.1. Algeria
- 9.6.2.2. Egypt
- 9.6.2.3. Israel
- 9.6.2.4. Kuwait
- 9.6.2.5. Nigeria
- 9.6.2.6. Saudi Arabia
- 9.6.2.7. South Africa
- 9.6.2.8. Turkey
- 9.6.2.9. The UAE
- 9.6.2.10. Rest of MEA
- 10. Global Dengue Vaccine Market Analysis, Opportunity and Forecast, By Region , 2016-2032
- 10.1. Global Dengue Vaccine Market Analysis by Region : Introduction
- 10.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Region , 2016-2032
- 10.2.1. North America
- 10.2.2. Western Europe
- 10.2.3. Eastern Europe
- 10.2.4. APAC
- 10.2.5. Latin America
- 10.2.6. Middle East & Africa
- 11. Global Dengue Vaccine Market Competitive Landscape, Market Share Analysis, and Company Profiles
- 11.1. Market Share Analysis
- 11.2. Company Profiles
- 11.3. Sanofi Pasteur
- 11.3.1. Company Overview
- 11.3.2. Financial Highlights
- 11.3.3. Product Portfolio
- 11.3.4. SWOT Analysis
- 11.3.5. Key Strategies and Developments
- 11.4. Takeda Pharmaceutical Company
- 11.4.1. Company Overview
- 11.4.2. Financial Highlights
- 11.4.3. Product Portfolio
- 11.4.4. SWOT Analysis
- 11.4.5. Key Strategies and Developments
- 11.5. Biological E Limited
- 11.5.1. Company Overview
- 11.5.2. Financial Highlights
- 11.5.3. Product Portfolio
- 11.5.4. SWOT Analysis
- 11.5.5. Key Strategies and Developments
- 11.6. Panacea Biotec
- 11.6.1. Company Overview
- 11.6.2. Financial Highlights
- 11.6.3. Product Portfolio
- 11.6.4. SWOT Analysis
- 11.6.5. Key Strategies and Developments
- 11.7. Serum Institute of India Pvt. Ltd
- 11.7.1. Company Overview
- 11.7.2. Financial Highlights
- 11.7.3. Product Portfolio
- 11.7.4. SWOT Analysis
- 11.7.5. Key Strategies and Developments
- 11.8. GeneOne Life Science
- 11.8.1. Company Overview
- 11.8.2. Financial Highlights
- 11.8.3. Product Portfolio
- 11.8.4. SWOT Analysis
- 11.8.5. Key Strategies and Developments
- 11.9. Medigen Vaccine Biologics
- 11.9.1. Company Overview
- 11.9.2. Financial Highlights
- 11.9.3. Product Portfolio
- 11.9.4. SWOT Analysis
- 11.9.5. Key Strategies and Developments
- 11.10. Panacea Biotec
- 11.10.1. Company Overview
- 11.10.2. Financial Highlights
- 11.10.3. Product Portfolio
- 11.10.4. SWOT Analysis
- 11.10.5. Key Strategies and Developments
- 11.11. Butantan Institute
- 11.11.1. Company Overview
- 11.11.2. Financial Highlights
- 11.11.3. Product Portfolio
- 11.11.4. SWOT Analysis
- 11.11.5. Key Strategies and Developments
- 11.12. Sun Pharmaceutical Industries Ltd
- 11.12.1. Company Overview
- 11.12.2. Financial Highlights
- 11.12.3. Product Portfolio
- 11.12.4. SWOT Analysis
- 11.12.5. Key Strategies and Developments
- 12. Assumptions and Acronyms
- 13. Research Methodology
- 14. Contact
- Figure 1: Global Dengue Vaccine Market Revenue (US$ Mn) Market Share by By Product in 2022
- Figure 2: Global Dengue Vaccine Market Attractiveness Analysis by By Product, 2016-2032
- Figure 3: Global Dengue Vaccine Market Revenue (US$ Mn) Market Share by By Vaccine Typein 2022
- Figure 4: Global Dengue Vaccine Market Attractiveness Analysis by By Vaccine Type, 2016-2032
- Figure 5: Global Dengue Vaccine Market Revenue (US$ Mn) Market Share by By End-Userin 2022
- Figure 6: Global Dengue Vaccine Market Attractiveness Analysis by By End-User, 2016-2032
- Figure 7: Global Dengue Vaccine Market Revenue (US$ Mn) Market Share by Region in 2022
- Figure 8: Global Dengue Vaccine Market Attractiveness Analysis by Region, 2016-2032
- Figure 9: Global Dengue Vaccine Market Revenue (US$ Mn) (2016-2032)
- Figure 10: Global Dengue Vaccine Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Figure 11: Global Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Figure 12: Global Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Vaccine Type (2016-2032)
- Figure 13: Global Dengue Vaccine Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Figure 14: Global Dengue Vaccine Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
- Figure 15: Global Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Figure 16: Global Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Vaccine Type (2016-2032)
- Figure 17: Global Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Figure 18: Global Dengue Vaccine Market Share Comparison by Region (2016-2032)
- Figure 19: Global Dengue Vaccine Market Share Comparison by By Product (2016-2032)
- Figure 20: Global Dengue Vaccine Market Share Comparison by By Vaccine Type (2016-2032)
- Figure 21: Global Dengue Vaccine Market Share Comparison by By End-User (2016-2032)
- Figure 22: North America Dengue Vaccine Market Revenue (US$ Mn) Market Share by By Productin 2022
- Figure 23: North America Dengue Vaccine Market Attractiveness Analysis by By Product, 2016-2032
- Figure 24: North America Dengue Vaccine Market Revenue (US$ Mn) Market Share by By Vaccine Typein 2022
- Figure 25: North America Dengue Vaccine Market Attractiveness Analysis by By Vaccine Type, 2016-2032
- Figure 26: North America Dengue Vaccine Market Revenue (US$ Mn) Market Share by By End-Userin 2022
- Figure 27: North America Dengue Vaccine Market Attractiveness Analysis by By End-User, 2016-2032
- Figure 28: North America Dengue Vaccine Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 29: North America Dengue Vaccine Market Attractiveness Analysis by Country, 2016-2032
- Figure 30: North America Dengue Vaccine Market Revenue (US$ Mn) (2016-2032)
- Figure 31: North America Dengue Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 32: North America Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Figure 33: North America Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Vaccine Type (2016-2032)
- Figure 34: North America Dengue Vaccine Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Figure 35: North America Dengue Vaccine Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 36: North America Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Figure 37: North America Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Vaccine Type (2016-2032)
- Figure 38: North America Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Figure 39: North America Dengue Vaccine Market Share Comparison by Country (2016-2032)
- Figure 40: North America Dengue Vaccine Market Share Comparison by By Product (2016-2032)
- Figure 41: North America Dengue Vaccine Market Share Comparison by By Vaccine Type (2016-2032)
- Figure 42: North America Dengue Vaccine Market Share Comparison by By End-User (2016-2032)
- Figure 43: Western Europe Dengue Vaccine Market Revenue (US$ Mn) Market Share by By Productin 2022
- Figure 44: Western Europe Dengue Vaccine Market Attractiveness Analysis by By Product, 2016-2032
- Figure 45: Western Europe Dengue Vaccine Market Revenue (US$ Mn) Market Share by By Vaccine Typein 2022
- Figure 46: Western Europe Dengue Vaccine Market Attractiveness Analysis by By Vaccine Type, 2016-2032
- Figure 47: Western Europe Dengue Vaccine Market Revenue (US$ Mn) Market Share by By End-Userin 2022
- Figure 48: Western Europe Dengue Vaccine Market Attractiveness Analysis by By End-User, 2016-2032
- Figure 49: Western Europe Dengue Vaccine Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 50: Western Europe Dengue Vaccine Market Attractiveness Analysis by Country, 2016-2032
- Figure 51: Western Europe Dengue Vaccine Market Revenue (US$ Mn) (2016-2032)
- Figure 52: Western Europe Dengue Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 53: Western Europe Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Figure 54: Western Europe Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Vaccine Type (2016-2032)
- Figure 55: Western Europe Dengue Vaccine Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Figure 56: Western Europe Dengue Vaccine Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 57: Western Europe Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Figure 58: Western Europe Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Vaccine Type (2016-2032)
- Figure 59: Western Europe Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Figure 60: Western Europe Dengue Vaccine Market Share Comparison by Country (2016-2032)
- Figure 61: Western Europe Dengue Vaccine Market Share Comparison by By Product (2016-2032)
- Figure 62: Western Europe Dengue Vaccine Market Share Comparison by By Vaccine Type (2016-2032)
- Figure 63: Western Europe Dengue Vaccine Market Share Comparison by By End-User (2016-2032)
- Figure 64: Eastern Europe Dengue Vaccine Market Revenue (US$ Mn) Market Share by By Productin 2022
- Figure 65: Eastern Europe Dengue Vaccine Market Attractiveness Analysis by By Product, 2016-2032
- Figure 66: Eastern Europe Dengue Vaccine Market Revenue (US$ Mn) Market Share by By Vaccine Typein 2022
- Figure 67: Eastern Europe Dengue Vaccine Market Attractiveness Analysis by By Vaccine Type, 2016-2032
- Figure 68: Eastern Europe Dengue Vaccine Market Revenue (US$ Mn) Market Share by By End-Userin 2022
- Figure 69: Eastern Europe Dengue Vaccine Market Attractiveness Analysis by By End-User, 2016-2032
- Figure 70: Eastern Europe Dengue Vaccine Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 71: Eastern Europe Dengue Vaccine Market Attractiveness Analysis by Country, 2016-2032
- Figure 72: Eastern Europe Dengue Vaccine Market Revenue (US$ Mn) (2016-2032)
- Figure 73: Eastern Europe Dengue Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 74: Eastern Europe Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Figure 75: Eastern Europe Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Vaccine Type (2016-2032)
- Figure 76: Eastern Europe Dengue Vaccine Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Figure 77: Eastern Europe Dengue Vaccine Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 78: Eastern Europe Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Figure 79: Eastern Europe Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Vaccine Type (2016-2032)
- Figure 80: Eastern Europe Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Figure 81: Eastern Europe Dengue Vaccine Market Share Comparison by Country (2016-2032)
- Figure 82: Eastern Europe Dengue Vaccine Market Share Comparison by By Product (2016-2032)
- Figure 83: Eastern Europe Dengue Vaccine Market Share Comparison by By Vaccine Type (2016-2032)
- Figure 84: Eastern Europe Dengue Vaccine Market Share Comparison by By End-User (2016-2032)
- Figure 85: APAC Dengue Vaccine Market Revenue (US$ Mn) Market Share by By Productin 2022
- Figure 86: APAC Dengue Vaccine Market Attractiveness Analysis by By Product, 2016-2032
- Figure 87: APAC Dengue Vaccine Market Revenue (US$ Mn) Market Share by By Vaccine Typein 2022
- Figure 88: APAC Dengue Vaccine Market Attractiveness Analysis by By Vaccine Type, 2016-2032
- Figure 89: APAC Dengue Vaccine Market Revenue (US$ Mn) Market Share by By End-Userin 2022
- Figure 90: APAC Dengue Vaccine Market Attractiveness Analysis by By End-User, 2016-2032
- Figure 91: APAC Dengue Vaccine Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 92: APAC Dengue Vaccine Market Attractiveness Analysis by Country, 2016-2032
- Figure 93: APAC Dengue Vaccine Market Revenue (US$ Mn) (2016-2032)
- Figure 94: APAC Dengue Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 95: APAC Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Figure 96: APAC Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Vaccine Type (2016-2032)
- Figure 97: APAC Dengue Vaccine Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Figure 98: APAC Dengue Vaccine Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 99: APAC Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Figure 100: APAC Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Vaccine Type (2016-2032)
- Figure 101: APAC Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Figure 102: APAC Dengue Vaccine Market Share Comparison by Country (2016-2032)
- Figure 103: APAC Dengue Vaccine Market Share Comparison by By Product (2016-2032)
- Figure 104: APAC Dengue Vaccine Market Share Comparison by By Vaccine Type (2016-2032)
- Figure 105: APAC Dengue Vaccine Market Share Comparison by By End-User (2016-2032)
- Figure 106: Latin America Dengue Vaccine Market Revenue (US$ Mn) Market Share by By Productin 2022
- Figure 107: Latin America Dengue Vaccine Market Attractiveness Analysis by By Product, 2016-2032
- Figure 108: Latin America Dengue Vaccine Market Revenue (US$ Mn) Market Share by By Vaccine Typein 2022
- Figure 109: Latin America Dengue Vaccine Market Attractiveness Analysis by By Vaccine Type, 2016-2032
- Figure 110: Latin America Dengue Vaccine Market Revenue (US$ Mn) Market Share by By End-Userin 2022
- Figure 111: Latin America Dengue Vaccine Market Attractiveness Analysis by By End-User, 2016-2032
- Figure 112: Latin America Dengue Vaccine Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 113: Latin America Dengue Vaccine Market Attractiveness Analysis by Country, 2016-2032
- Figure 114: Latin America Dengue Vaccine Market Revenue (US$ Mn) (2016-2032)
- Figure 115: Latin America Dengue Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 116: Latin America Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Figure 117: Latin America Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Vaccine Type (2016-2032)
- Figure 118: Latin America Dengue Vaccine Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Figure 119: Latin America Dengue Vaccine Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 120: Latin America Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Figure 121: Latin America Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Vaccine Type (2016-2032)
- Figure 122: Latin America Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Figure 123: Latin America Dengue Vaccine Market Share Comparison by Country (2016-2032)
- Figure 124: Latin America Dengue Vaccine Market Share Comparison by By Product (2016-2032)
- Figure 125: Latin America Dengue Vaccine Market Share Comparison by By Vaccine Type (2016-2032)
- Figure 126: Latin America Dengue Vaccine Market Share Comparison by By End-User (2016-2032)
- Figure 127: Middle East & Africa Dengue Vaccine Market Revenue (US$ Mn) Market Share by By Productin 2022
- Figure 128: Middle East & Africa Dengue Vaccine Market Attractiveness Analysis by By Product, 2016-2032
- Figure 129: Middle East & Africa Dengue Vaccine Market Revenue (US$ Mn) Market Share by By Vaccine Typein 2022
- Figure 130: Middle East & Africa Dengue Vaccine Market Attractiveness Analysis by By Vaccine Type, 2016-2032
- Figure 131: Middle East & Africa Dengue Vaccine Market Revenue (US$ Mn) Market Share by By End-Userin 2022
- Figure 132: Middle East & Africa Dengue Vaccine Market Attractiveness Analysis by By End-User, 2016-2032
- Figure 133: Middle East & Africa Dengue Vaccine Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 134: Middle East & Africa Dengue Vaccine Market Attractiveness Analysis by Country, 2016-2032
- Figure 135: Middle East & Africa Dengue Vaccine Market Revenue (US$ Mn) (2016-2032)
- Figure 136: Middle East & Africa Dengue Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 137: Middle East & Africa Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Figure 138: Middle East & Africa Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Vaccine Type (2016-2032)
- Figure 139: Middle East & Africa Dengue Vaccine Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Figure 140: Middle East & Africa Dengue Vaccine Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 141: Middle East & Africa Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Figure 142: Middle East & Africa Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Vaccine Type (2016-2032)
- Figure 143: Middle East & Africa Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Figure 144: Middle East & Africa Dengue Vaccine Market Share Comparison by Country (2016-2032)
- Figure 145: Middle East & Africa Dengue Vaccine Market Share Comparison by By Product (2016-2032)
- Figure 146: Middle East & Africa Dengue Vaccine Market Share Comparison by By Vaccine Type (2016-2032)
- Figure 147: Middle East & Africa Dengue Vaccine Market Share Comparison by By End-User (2016-2032)
- Table 1: Global Dengue Vaccine Market Comparison by By Product (2016-2032)
- Table 2: Global Dengue Vaccine Market Comparison by By Vaccine Type (2016-2032)
- Table 3: Global Dengue Vaccine Market Comparison by By End-User (2016-2032)
- Table 4: Global Dengue Vaccine Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Table 5: Global Dengue Vaccine Market Revenue (US$ Mn) (2016-2032)
- Table 6: Global Dengue Vaccine Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Table 7: Global Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Table 8: Global Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Vaccine Type (2016-2032)
- Table 9: Global Dengue Vaccine Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Table 10: Global Dengue Vaccine Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
- Table 11: Global Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Table 12: Global Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Vaccine Type (2016-2032)
- Table 13: Global Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Table 14: Global Dengue Vaccine Market Share Comparison by Region (2016-2032)
- Table 15: Global Dengue Vaccine Market Share Comparison by By Product (2016-2032)
- Table 16: Global Dengue Vaccine Market Share Comparison by By Vaccine Type (2016-2032)
- Table 17: Global Dengue Vaccine Market Share Comparison by By End-User (2016-2032)
- Table 18: North America Dengue Vaccine Market Comparison by By Vaccine Type (2016-2032)
- Table 19: North America Dengue Vaccine Market Comparison by By End-User (2016-2032)
- Table 20: North America Dengue Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 21: North America Dengue Vaccine Market Revenue (US$ Mn) (2016-2032)
- Table 22: North America Dengue Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 23: North America Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Table 24: North America Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Vaccine Type (2016-2032)
- Table 25: North America Dengue Vaccine Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Table 26: North America Dengue Vaccine Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 27: North America Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Table 28: North America Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Vaccine Type (2016-2032)
- Table 29: North America Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Table 30: North America Dengue Vaccine Market Share Comparison by Country (2016-2032)
- Table 31: North America Dengue Vaccine Market Share Comparison by By Product (2016-2032)
- Table 32: North America Dengue Vaccine Market Share Comparison by By Vaccine Type (2016-2032)
- Table 33: North America Dengue Vaccine Market Share Comparison by By End-User (2016-2032)
- Table 34: Western Europe Dengue Vaccine Market Comparison by By Product (2016-2032)
- Table 35: Western Europe Dengue Vaccine Market Comparison by By Vaccine Type (2016-2032)
- Table 36: Western Europe Dengue Vaccine Market Comparison by By End-User (2016-2032)
- Table 37: Western Europe Dengue Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 38: Western Europe Dengue Vaccine Market Revenue (US$ Mn) (2016-2032)
- Table 39: Western Europe Dengue Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 40: Western Europe Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Table 41: Western Europe Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Vaccine Type (2016-2032)
- Table 42: Western Europe Dengue Vaccine Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Table 43: Western Europe Dengue Vaccine Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 44: Western Europe Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Table 45: Western Europe Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Vaccine Type (2016-2032)
- Table 46: Western Europe Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Table 47: Western Europe Dengue Vaccine Market Share Comparison by Country (2016-2032)
- Table 48: Western Europe Dengue Vaccine Market Share Comparison by By Product (2016-2032)
- Table 49: Western Europe Dengue Vaccine Market Share Comparison by By Vaccine Type (2016-2032)
- Table 50: Western Europe Dengue Vaccine Market Share Comparison by By End-User (2016-2032)
- Table 51: Eastern Europe Dengue Vaccine Market Comparison by By Product (2016-2032)
- Table 52: Eastern Europe Dengue Vaccine Market Comparison by By Vaccine Type (2016-2032)
- Table 53: Eastern Europe Dengue Vaccine Market Comparison by By End-User (2016-2032)
- Table 54: Eastern Europe Dengue Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 55: Eastern Europe Dengue Vaccine Market Revenue (US$ Mn) (2016-2032)
- Table 56: Eastern Europe Dengue Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 57: Eastern Europe Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Table 58: Eastern Europe Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Vaccine Type (2016-2032)
- Table 59: Eastern Europe Dengue Vaccine Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Table 60: Eastern Europe Dengue Vaccine Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 61: Eastern Europe Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Table 62: Eastern Europe Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Vaccine Type (2016-2032)
- Table 63: Eastern Europe Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Table 64: Eastern Europe Dengue Vaccine Market Share Comparison by Country (2016-2032)
- Table 65: Eastern Europe Dengue Vaccine Market Share Comparison by By Product (2016-2032)
- Table 66: Eastern Europe Dengue Vaccine Market Share Comparison by By Vaccine Type (2016-2032)
- Table 67: Eastern Europe Dengue Vaccine Market Share Comparison by By End-User (2016-2032)
- Table 68: APAC Dengue Vaccine Market Comparison by By Product (2016-2032)
- Table 69: APAC Dengue Vaccine Market Comparison by By Vaccine Type (2016-2032)
- Table 70: APAC Dengue Vaccine Market Comparison by By End-User (2016-2032)
- Table 71: APAC Dengue Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 72: APAC Dengue Vaccine Market Revenue (US$ Mn) (2016-2032)
- Table 73: APAC Dengue Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 74: APAC Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Table 75: APAC Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Vaccine Type (2016-2032)
- Table 76: APAC Dengue Vaccine Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Table 77: APAC Dengue Vaccine Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 78: APAC Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Table 79: APAC Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Vaccine Type (2016-2032)
- Table 80: APAC Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Table 81: APAC Dengue Vaccine Market Share Comparison by Country (2016-2032)
- Table 82: APAC Dengue Vaccine Market Share Comparison by By Product (2016-2032)
- Table 83: APAC Dengue Vaccine Market Share Comparison by By Vaccine Type (2016-2032)
- Table 84: APAC Dengue Vaccine Market Share Comparison by By End-User (2016-2032)
- Table 85: Latin America Dengue Vaccine Market Comparison by By Product (2016-2032)
- Table 86: Latin America Dengue Vaccine Market Comparison by By Vaccine Type (2016-2032)
- Table 87: Latin America Dengue Vaccine Market Comparison by By End-User (2016-2032)
- Table 88: Latin America Dengue Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 89: Latin America Dengue Vaccine Market Revenue (US$ Mn) (2016-2032)
- Table 90: Latin America Dengue Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 91: Latin America Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Table 92: Latin America Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Vaccine Type (2016-2032)
- Table 93: Latin America Dengue Vaccine Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Table 94: Latin America Dengue Vaccine Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 95: Latin America Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Table 96: Latin America Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Vaccine Type (2016-2032)
- Table 97: Latin America Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Table 98: Latin America Dengue Vaccine Market Share Comparison by Country (2016-2032)
- Table 99: Latin America Dengue Vaccine Market Share Comparison by By Product (2016-2032)
- Table 100: Latin America Dengue Vaccine Market Share Comparison by By Vaccine Type (2016-2032)
- Table 101: Latin America Dengue Vaccine Market Share Comparison by By End-User (2016-2032)
- Table 102: Middle East & Africa Dengue Vaccine Market Comparison by By Product (2016-2032)
- Table 103: Middle East & Africa Dengue Vaccine Market Comparison by By Vaccine Type (2016-2032)
- Table 104: Middle East & Africa Dengue Vaccine Market Comparison by By End-User (2016-2032)
- Table 105: Middle East & Africa Dengue Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 106: Middle East & Africa Dengue Vaccine Market Revenue (US$ Mn) (2016-2032)
- Table 107: Middle East & Africa Dengue Vaccine Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 108: Middle East & Africa Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Product (2016-2032)
- Table 109: Middle East & Africa Dengue Vaccine Market Revenue (US$ Mn) Comparison by By Vaccine Type (2016-2032)
- Table 110: Middle East & Africa Dengue Vaccine Market Revenue (US$ Mn) Comparison by By End-User (2016-2032)
- Table 111: Middle East & Africa Dengue Vaccine Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 112: Middle East & Africa Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Product (2016-2032)
- Table 113: Middle East & Africa Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By Vaccine Type (2016-2032)
- Table 114: Middle East & Africa Dengue Vaccine Market Y-o-Y Growth Rate Comparison by By End-User (2016-2032)
- Table 115: Middle East & Africa Dengue Vaccine Market Share Comparison by Country (2016-2032)
- Table 116: Middle East & Africa Dengue Vaccine Market Share Comparison by By Product (2016-2032)
- Table 117: Middle East & Africa Dengue Vaccine Market Share Comparison by By Vaccine Type (2016-2032)
- Table 118: Middle East & Africa Dengue Vaccine Market Share Comparison by By End-User (2016-2032)
- 1. Executive Summary
Inquiry Form
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
Request for Customization
OUR CLIENTS
Don't just take our word. We are trusted by these great companies!